Acumen Pharmaceuticals, Inc. (ABOS)
| Market Cap | 15.20M -88.9% |
| Revenue (ttm) | n/a |
| Net Income | -103.96M |
| EPS | -1.55 |
| Shares Out | 72.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,906,811 |
| Open | 0.3444 |
| Previous Close | 2.2900 |
| Day's Range | 0.2092 - 0.3520 |
| 52-Week Range | 0.2092 - 3.6000 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 2.40 (+1,042.31%) |
| Earnings Date | Oct 26, 2026 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABOS stock is "Hold." The 12-month stock price target is $2.4, which is an increase of 1,042.31% from the latest price.
News
Acumen downgraded to Underweight from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Acumen (ABOS) to Underweight from Overweight without a price target after sabirnetug failed to hit primary and key secondary endpoints in the Phase 2 Alzheimer’s disease s...
Acumen downgraded to Neutral from Buy at Citi
Citi analyst Geoff Meacham downgraded Acumen (ABOS) to Neutral from Buy with a price target of $1, down from $5, after the sabirnetug Phase 2 trial did not meet the…
Acumen downgraded to Hold from Buy at Stifel
Stifel downgraded Acumen (ABOS) to Hold from Buy with a price target of $1, down from $10, following the company’s announcement that both the 35mg/kg and 50mg/kg doses for sabirnetug…
Acumen reports ALTITUDE-AD clinical trial did not meet primary endpoint
Acumen (ABOS) announced that initial topline data from its Phase 2 ALTITUDE-AD clinical trial of sabirnetug in participants with early AD did not meet its primary endpoint of change from…
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADR...
Acumen files $500M mixed securities shelf
16:23 EDT Acumen (ABOS) files $500M mixed securities shelf
Acumen Pharmaceuticals Earnings Call Transcript: Q3 2026
ALTITUDE-AD results are expected in November, with management viewing 30% iADRS slowing as a clear success threshold. Quarter-end cash of ~$79m is expected to support current activities into early 2027; EBD candidates are advancing toward a mid-2027 IND.
Acumen Pharmaceuticals Earnings release: Q3 2026
Acumen Pharmaceuticals released its Q3 2026 earnings on October 26, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Quarterly report: Q3 2026
Acumen Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 26, 2026.
Acumen Pharmaceuticals Registration statement: Registration filing
Acumen Pharmaceuticals filed a registration statement on October 26, 2026, providing details about a securities offering with the SEC.
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain ...
Acumen Pharmaceuticals Slides: Corporate presentation
Acumen Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyl...
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...
Acumen Pharmaceuticals Transcript: Investor Day 2026
A novel anti-Aβ oligomer antibody is advancing through a pivotal phase II trial in early Alzheimer's, aiming to differentiate on both efficacy and safety. Enhanced brain delivery candidates show promising preclinical results, with IND filing targeted for 2027. Market growth is driven by improved diagnostics and a large, underserved patient population.
Acumen Pharmaceuticals Slides: FY 2026
Acumen Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 16, 2026.
Citi ups Acumen target, opens ‘upside 90-day catalyst watch’
Citi analyst Geoff Meacham raised the firm’s price target on Acumen (ABOS) to $5 from $4 and keeps a Buy rating on the shares. Citi also added an “upside 90-day…
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
The Alzheimer's market is rapidly expanding, with a novel phase II therapy targeting toxic A-beta oligomers expected to report pivotal data in late 2026. Robust trial design, strong KOL support, and an innovative brain delivery platform position the pipeline for future growth.
Acumen Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Sabirnetug, a highly selective A-beta oligomer antibody, is in phase II for early Alzheimer's, with data expected late 2024. The Enhanced Brain Delivery program, leveraging JCR's technology, targets an IND in mid-2027, with two candidates in development. ALTITUDE results will validate the oligomer hypothesis and guide future pipeline decisions.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloi...
Acumen Pharmaceuticals Earnings Call Transcript: Q2 2026
Sabirnetug's phase II ALTITUDE-AD trial remains on track for late 2026 top-line results, with robust clinical and biomarker endpoints and strong financial runway into 2027. Two new EBD candidates advance preclinical development, and digital and fluid biomarker strategies are expanding.
Acumen Pharmaceuticals Earnings release: Q2 2026
Acumen Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Quarterly report: Q2 2026
Acumen Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...